These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38258464)

  • 1. Seroprevalence of severe acute respiratory syndrome coronavirus 2 N antibodies between December 2021 and march 2023 in Japan.
    Yamayoshi S; Nagai E; Mitamura K; Hagihara M; Kobayashi R; Takahashi S; Shibata A; Uwamino Y; Hasegawa N; Iqbal A; Kamimaki I; Iwatsuki-Horimoto K; Nagamura-Inoue T; Kawaoka Y
    Epidemiol Infect; 2024 Jan; 152():e24. PubMed ID: 38258464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020-March 2022.
    Yamayoshi S; Iwatsuki-Horimoto K; Okuda M; Ujie M; Yasuhara A; Murakami J; Duong C; Hamabata T; Ito M; Chiba S; Kobayashi R; Takahashi S; Mitamura K; Hagihara M; Shibata A; Uwamino Y; Hasegawa N; Ebina T; Izumi A; Kato H; Nakajima H; Sugaya N; Seki Y; Iqbal A; Kamimaki I; Yamazaki M; Kawaoka Y; Furuse Y
    Emerg Infect Dis; 2022 Nov; 28(11):2198-2205. PubMed ID: 36198306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Seroprevalence of SARS-CoV-2 in Children During Early COVID-19 Pandemic in Korea: A Nationwide, Population-Based Study.
    Lee J; Choe YJ; Minn D; Kim JH
    J Korean Med Sci; 2022 Nov; 37(44):e314. PubMed ID: 36377292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National seroepidemiological study of COVID-19 after the initial rollout of vaccines: Before and at the peak of the Omicron-dominant period in Japan.
    Arashiro T; Arai S; Kinoshita R; Otani K; Miyamoto S; Yoneoka D; Kamigaki T; Takahashi H; Hibino H; Okuyama M; Hayashi A; Kikuchi F; Morino S; Takanashi S; Wakita T; Tanaka-Taya K; Suzuki T; Suzuki M
    Influenza Other Respir Viruses; 2023 Feb; 17(2):e13094. PubMed ID: 36824391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program.
    Stone M; Di Germanio C; Wright DJ; Sulaeman H; Dave H; Fink RV; Notari EP; Green V; Strauss D; Kessler D; Destree M; Saa P; Williamson PC; Simmons G; Stramer SL; Opsomer J; Jones JM; Kleinman S; Busch MP;
    Clin Infect Dis; 2022 Mar; 74(5):871-881. PubMed ID: 34111244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 Seroprevalence among Healthcare Workers in General Hospitals and Clinics in Japan.
    Yoshihara T; Ito K; Zaitsu M; Chung E; Aoyagi I; Kaji Y; Tsuru T; Yonemura T; Yamaguchi K; Nakayama S; Tanaka Y; Yurino N; Koyanagi H; Matsuki S; Urae R; Irie S
    Int J Environ Res Public Health; 2021 Apr; 18(7):. PubMed ID: 33916399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic.
    Palmateer NE; Dickson E; Furrie E; Godber I; Goldberg DJ; Gousias P; Jarvis L; Mathie L; Mavin S; McMenamin J; McNeilly TN; Murcia P; Murray J; Reid G; Robertson C; Templeton K; von Wissmann B; Wallace LA; Waugh C; McAuley A
    Public Health; 2021 Sep; 198():102-105. PubMed ID: 34411992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study.
    Suntronwong N; Vichaiwattana P; Klinfueng S; Puenpa J; Kanokudom S; Assawakosri S; Chansaenroj J; Srimuan D; Thatsanatorn T; Songtaisarana S; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
    PLoS One; 2023; 18(4):e0279147. PubMed ID: 37104299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies.
    Bergeri I; Whelan MG; Ware H; Subissi L; Nardone A; Lewis HC; Li Z; Ma X; Valenciano M; Cheng B; Al Ariqi L; Rashidian A; Okeibunor J; Azim T; Wijesinghe P; Le LV; Vaughan A; Pebody R; Vicari A; Yan T; Yanes-Lane M; Cao C; Clifton DA; Cheng MP; Papenburg J; Buckeridge D; Bobrovitz N; Arora RK; Van Kerkhove MD;
    PLoS Med; 2022 Nov; 19(11):e1004107. PubMed ID: 36355774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-Vaccination Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in Workers at Three Japanese Hospitals.
    Takayama Y; Komatsu T; Wada T; Nihonyanagi S; Hoshiyama T; Moriya T; Shimamura S; Kajigaya N; Naito M; Takeuchi O; Bando Y; Watanabe M; Iwamura M; Hanaki H
    J Nippon Med Sch; 2022 Nov; 89(5):513-519. PubMed ID: 35644553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 Seroprevalence in Children from Western Romania, March to June 2021.
    Olariu TR; Craciun AC; Vlad DC; Dumitrascu V; Pop LL; Horhat F; Lupu MA
    Vector Borne Zoonotic Dis; 2022 Apr; 22(4):267-270. PubMed ID: 35384727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cumulative and undiagnosed SARS-CoV-2 infection among the staff of a medical research centre in Tokyo after the emergence of variants.
    Mizoue T; Yamamoto S; Oshiro Y; Inamura N; Nemoto T; Horii K; Okudera K; Konishi M; Ozeki M; Sugiyama H; Aoyanagi N; Sugiura W; Ohmagari N
    Epidemiol Infect; 2023 Mar; 151():e48. PubMed ID: 36960731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased breadth and neutralization of antibodies against SARS-CoV-2 variants after infection and vaccination: A serosurveillance study in pediatric patients of Southern Switzerland.
    Mazzara C; Bassi J; Silacci-Fregni C; Muoio F; Passini N; Corti D; Simonetti GD; Vanoni F; Kottanattu L; Piccoli L
    Eur J Pediatr; 2024 Mar; 183(3):1425-1434. PubMed ID: 38175262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020-2022.
    Solastie A; Nieminen T; Ekström N; Nohynek H; Lehtonen L; Palmu AA; Melin M
    Emerg Microbes Infect; 2023 Dec; 12(2):2222849. PubMed ID: 37289188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of saliva immunoglobulin A antibodies reactive with severe acute respiratory syndrome coronavirus 2 among Japanese people unexposed to the virus.
    Tsukinoki K; Yamamoto T; Saito J; Sakaguchi W; Iguchi K; Inoue Y; Ishii S; Sato C; Yokoyama M; Shiraishi Y; Kato N; Shimada H; Makabe A; Saito A; Tanji M; Nagaoka I; Saruta J; Yamaguchi T; Kimoto S; Yamaguchi H
    Microbiol Immunol; 2022 Aug; 66(8):403-410. PubMed ID: 35607844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence kinetics of SARS-CoV-2 antibodies in pediatric patients visiting a hospital during COVID-19 pandemic in Japan.
    Hashimoto T; Yahiro T; Khan S; Kimitsuki K; Suzuki M; Fujimoto T; Tanaka T; Saito N; Hiramatsu K; Nishizono A
    J Infect Chemother; 2024 Feb; 30(2):169-171. PubMed ID: 37734592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of SARS-CoV-2 in Pakistan: an update on epidemiological trends.
    Waqar M; Wahid B; Idrees M; Ali M; Rehman Z
    Z Naturforsch C J Biosci; 2021 Sep; 76(9-10):425-429. PubMed ID: 34161693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.
    Tunheim G; Rø GØI; Chopra A; Aase A; Kran AB; Vaage JT; Lund-Johansen F; Hungnes O
    Influenza Other Respir Viruses; 2022 Nov; 16(6):1004-1013. PubMed ID: 35770841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-Weighted Seroprevalence From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Vaccination, and Hybrid Immunity Among US Blood Donations From January to December 2021.
    Busch MP; Stramer SL; Stone M; Yu EA; Grebe E; Notari E; Saa P; Ferg R; Manrique IM; Weil N; Fink RV; Levy ME; Green V; Cyrus S; Williamson PC; Haynes J; Groves J; Krysztof D; Custer B; Kleinman S; Biggerstaff BJ; Opsomer JD; Jones JM
    Clin Infect Dis; 2022 Oct; 75(Suppl 2):S254-S263. PubMed ID: 35684973
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.